News Category
Global pediatric stroke deaths and disability have declined since 1990, but adolescent incidence and hemorrhagic stroke mortality in low-SDI regions a...
Quantum BioPharma is advancing a multi-pronged strategy that combines drug development, consumer wellness, and royalty partnerships to address neurolo...
Annovis Bio's proposed public offering aims to raise capital to advance its lead drug candidate buntanetap through Phase 3 trials for Alzheimer's and ...
Tonix Pharmaceuticals' upcoming presentation at the Guggenheim Healthcare Innovation Conference highlights its commercial-stage CNS portfolio, includi...
Quantum BioPharma advances a broad strategy combining drug development, consumer wellness, and royalty partnerships to address the massive unmet need ...
Quantum BioPharma's unbuzzd supplement, which showed significantly lower estimated blood alcohol concentration and improved alertness versus placebo i...
Quantum BioPharma's unbuzzd supplement, designed to support alcohol metabolism, has drawn praise from Men's Fitness after a clinical trial showed prom...
Okogen has dosed the first patient in its Phase 1/2 EMERALD trial of Treyegen for acute infectious conjunctivitis, a milestone that could validate its...
Preliminary research shows that non-specialist health professionals, aided by AI and off-site expert review, can perform quality heart scans in mobile...
New preliminary research shows that out-of-hospital cardiac arrest ICU admissions rise sharply with extreme heat, particularly affecting women and old...
Catherine Cifuentes-Rojas has published a free five-question checklist to help biotherapeutics teams make disciplined early-stage investment decisions...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business marks a key step toward launching Phase 2 trials for Lucid-MS, a novel m...
Annovis Bio CEO Maria Maccecchini will present at two November biotechnology conferences, highlighting the company's clinical programs and upcoming mi...
NanoViricides' Phase IIA trial of NV-387 Oral Gummies for Ebola Bundibugyo is progressing, potentially offering the first oral treatment amid an outbr...
An early, mutated flu outbreak on the West Coast is prompting urgent vaccination calls and highlighting the need for decentralized testing tools from ...
Tonix Pharmaceuticals' TONMYA demonstrated significant improvements in fibromyalgia symptoms and physical function in Phase 3 trials, reinforcing its ...
Tonix Pharmaceuticals will report third-quarter 2026 financial results on Nov. 9, an event that will give investors a first detailed look at the comme...
Annovis Bio's three CTAD 2026 presentations on buntanetap's mechanism, Phase 3 trial design, and AI-driven blood-brain barrier prediction highlight th...
NeuroThera Labs has completed manufacturing and obtained European QP batch release for its SCI-110 investigational product, enabling shipment to clini...
BioVersys announced the publication of two Phase 1 studies showing BV100 achieves high lung concentrations and has a manageable drug interaction profi...
Quantum BioPharma's Unbuzzd alcohol recovery formulation gained mainstream attention through a Men's Fitness analysis of its clinical trial results, h...
NanoViricides announced positive juvenile animal safety results for its broad-spectrum antiviral NV-387, supporting potential pediatric clinical trial...
Quantum BioPharma's Unbuzzd alcohol recovery formulation was featured in a Men's Fitness article examining clinical trial results, highlighting both p...
Tonix Pharmaceuticals will present new data on TONMYA, the first new fibromyalgia treatment in over 15 years, at the 2026 IASP World Congress on Pain,...
New attention to measles-induced immune vulnerability underscores the urgent need for higher vaccine uptake and decentralized testing to prevent long-...
Tonix Pharmaceuticals will present its TNX-801 horsepox-based vaccine platform at a major European vaccine conference, highlighting a potential new to...
OrthodontiCell has secured sufficient capital to complete the remaining testing needed to support its application to begin a planned Phase II pivotal ...
hyperCORE International has elected a new executive team to lead its strategic scaling platform, aiming to accelerate growth for independent site netw...
Quantum BioPharma (NASDAQ: QNTM) has received FDA approval to begin Phase 2 testing of Lucid-MS, a first-in-class multiple sclerosis drug that targets...
The American Heart Association's selection of five health technology finalists highlights a push to overcome adoption barriers and accelerate innovati...
NanoViricides reports progress in its Phase IIA trial of NV-387 Oral Gummies for Ebola, potentially validating a broad-spectrum antiviral platform tha...
Nutriband Inc. (NASDAQ: NTRB) raised approximately $1.75 million through warrant exercises, funding the remaining clinical development and New Drug Ap...
Leksum LLC has signed an agreement with the Medical University of Vienna to conduct preparatory work for Phase I/II clinical trials of LK-ICU, a thera...
The American Heart Association has expanded its education portfolio with new resources to help clinicians implement the first-ever cardiovascular-kidn...
Newron Pharmaceuticals has received written feedback from the FDA on the clinical hold at U.S. study centers for its Phase 3 ENIGMA-TRS 2 trial, as th...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its neuroprotective Lucid-MS candidate into a Phase 2 trial, poten...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific to initiate a Phase 2 trial of Lucid-MS, a novel multiple sclero...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its novel neuroprotective multiple sclerosis drug Lucid-MS into a ...
XORTX Therapeutics is advancing XORLO, a reformulated gout treatment, toward an FDA new drug application next year, aiming to address tolerability iss...
Quantum BioPharma's study start-up agreement with Thermo Fisher for its Lucid-MS Phase 2 trial in multiple sclerosis marks a key step toward clinical ...
NanoViricides will present at the NIBA 153rd Investment Conference, highlighting its broad-spectrum antiviral NV-387, which is in Phase 2 trials for E...
Quantum BioPharma's study start-up agreement with Thermo Fisher for its Phase 2 Lucid-MS trial signals progress toward a potential first-in-class mult...
The CDSCO's authorization of Okogen's EMERALD Phase 1/2 study for Treyegen (OKG-0303) marks a significant step toward a much-needed dual-action treatm...
NanoViricides has provided details on its Phase II trial of NV-387 Oral Gummies for Ebola, highlighting the potential of an oral antiviral that could ...
Nutriband's five-year Nasdaq listing anniversary highlights its progress in developing an abuse-deterrent fentanyl patch, a product that could address...
Gianluca Cerri, MD, proposes a personal policy requiring emergency physicians to discuss medication-assisted treatment with opioid use disorder patien...
Stonegate Capital Partners updates coverage on Incannex Healthcare, highlighting the start of patient dosing in the DReAMzz trial and the company's 12...
AAG Zacheriel's debut novel The Vena Protocol: First Blood uses fiction to highlight how commercial pressures can compromise clinical trial data and e...
